11/21
03:09 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/13
03:01 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/5
04:41 pm
clls
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting [Yahoo! Finance]
Medium
Report
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting [Yahoo! Finance]
11/5
04:30 pm
clls
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
Low
Report
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
11/5
02:03 pm
clls
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/5
09:43 am
clls
Cellectis S.A. (NASDAQ: CLLS) had its price target lowered by analysts at Barclays PLC from $7.00 to $5.00. They now have an "overweight" rating on the stock.
Medium
Report
Cellectis S.A. (NASDAQ: CLLS) had its price target lowered by analysts at Barclays PLC from $7.00 to $5.00. They now have an "overweight" rating on the stock.
11/5
02:15 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/4
04:45 pm
clls
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 [Yahoo! Finance]
Medium
Report
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 [Yahoo! Finance]
11/4
04:30 pm
clls
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
Low
Report
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
10/30
04:30 pm
clls
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
Low
Report
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
10/28
02:03 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/22
02:10 am
clls
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress [Yahoo! Finance]
Low
Report
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress [Yahoo! Finance]
10/22
02:00 am
clls
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
Low
Report
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
10/20
02:08 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/12
02:04 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/4
02:12 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/26
02:11 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/20
05:13 am
clls
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Medium
Report
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
9/18
02:39 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/10
02:03 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/3
04:30 pm
clls
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
Low
Report
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
9/2
02:11 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
8/30
01:38 pm
clls
Cellectis: Cheap With Promising But Speculative Cancer Therapies [Seeking Alpha]
Low
Report
Cellectis: Cheap With Promising But Speculative Cancer Therapies [Seeking Alpha]
8/26
04:30 pm
clls
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Low
Report
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
8/25
02:06 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Neutral
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.